Samsung BioLogics - About the company
Samsung BioLogics is a public company based in Incheon (South Korea), founded in 2011. It operates as a CDMO focused on biologics development & manufacturing services. The company has 369 active competitors, including 41 funded and 53 that have exited. Its top competitors include companies like Novartis, Catalent and Surrozen.
Company Details
- Website
- samsungbiologics.com
Key Metrics
Founded Year
2011
Location
Incheon, South Korea
Stage
Public
Investors
Ranked
17th among 369 active competitors
Employee Count
1,998 as on Oct 05, 2025
Investment & Acquisitions
Exit Details
Public
Samsung BioLogics's IPO details
Samsung BioLogics got listed on Nov 10, 2016.
Click here to take a look at Samsung BioLogics's IPO in detail
Sign up to download Samsung BioLogics' company profile
Samsung BioLogics's funding and investors
Samsung BioLogics is a funded company. Samsung BioLogics has 2 institutional investors.
View details of Samsung BioLogics's funding rounds and investors
Samsung BioLogics' founders and board of directors
Founder? Claim ProfileSamsung BioLogics' employee count trend
Samsung BioLogics has 1,998 employees as of Oct 25. Here is Samsung BioLogics's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Samsung BioLogics's Competitors and alternates
Top competitors of Samsung BioLogics include Novartis, Catalent and Surrozen. Here is the list of Top 10 competitors of Samsung BioLogics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Novartis 1996, Basel (Switzerland), Public | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 | |
2nd | Catalent 2007, Somerset (United States), Acquired | Provider of development, manufacturing, and packaging solutions for medicines and supplements | - | 68/100 | |
3rd | Surrozen 2016, San Francisco (United States), Public | Pioneering targeted regenerative antibodies to repair tissue and restore organ function | $133M | 66/100 | |
4th | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | - | 62/100 | ||
5th | BioFactura 2004, Frederick (United States), Series B | Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $7.8M | 56/100 | |
6th | Full-Life Technologies 2021, Shanghai (China), Series C | Provider of discovery, development, production, and logistics services for of nuclear medicines | $200M | 56/100 | |
7th | Tirupati Medicare 1980, Paonta Sahib (India), Series B | Contract manufacturer of pharmaceutical products | $51.5M | 55/100 | |
8th | Acclinate 2020, Birmingham (United States), Series A | Provider of clinical trial services to biopharma sector | $12M | 54/100 | |
9th | AmplifyBio 2021, Hilliard (United States), Deadpooled | Provider of contract research, development, and manufacturing services for biologic drugs | $230M | 53/100 | |
10th | Curia 1991, Albany (United States), Acquired | Provider of drug research & development, testing, and consulting services | - | 52/100 | |
17th | Samsung BioLogics 2011, Incheon (South Korea), Public | CDMO focused on biologics development & manufacturing services | - | 46/100 |
Looking for more details on Samsung BioLogics's competitors? Click here to see the top ones
Samsung BioLogics's Investments and acquisitions
Samsung BioLogics has made 3 investments in companies including Arbor Biotechnologies and C₂N Diagnostics. Samsung BioLogics has also acquired 3 companies including Human Genome Sciences and Samsung Bioepis.Here is the list of investments & acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Dec 21, 2025 | Acquisition | 1992 | Rockville (United States) | |
Oct 30, 2025 | Investments | 2016 | Cambridge (United States) | |
Mar 13, 2025 | Investments | 2007 | St. Louis (United States) |
See all investments by Samsung BioLogics
News related to Samsung BioLogics
Media has covered Samsung BioLogics for a total of 55 events in the last 1 year, 31 of them have been about company updates and 3 about partnerships.
•
Samsung Biologics Seeks Injunction to Block Union’s First StrikeBusinesskorea•Apr 02, 2026•Samsung BioLogics
•
Samsung Biologics brings cell line services in-houseKorea Herald•Mar 23, 2026•Samsung BioLogics, GSK
•
Sandoz partners with Samsung Bioepis on biosimilars to expand pipeline.WebDisclosure•Mar 18, 2026•Samsung Bioepis, Sandoz, Samsung, Samsung BioLogics
•
Rapid Micro Biosystems Reports Record Q4 and Full Year 2025 ResultsGlobeNewswire•Mar 12, 2026•Rapid Micro Biosystems, Samsung BioLogics
•
Samsung Biologics, Eli Lilly to Launch Startup Hub in Koreamk.co.kr•Mar 11, 2026•Lilly, Samsung BioLogics, Celltrion
•
Eli Lilly to invest $500 mn in S. Korea biotech ecosystemmk.co.kr•Mar 10, 2026•Lilly, Samsung BioLogics
•
Cell and Gene Therapy Manufacturing Market Report Forecasts Significant GrowthPR Newswire•Mar 09, 2026•Soterbio, Cellipont, Credence Research Europe, Merck and 6 others
•
Biopharmaceutical CMO Market to Reach USD 76.20 Billion by 2035GlobeNewswire•Feb 24, 2026•Snsinsider, Lonza, Samsung BioLogics, Catalent
•
South Korean CDMO Giants Expand U.S. Production FacilitiesBusinesskorea•Feb 13, 2026•LOTTE BIOLOGICS, Celltrion, Samsung BioLogics
•
Samsung Biologics' PCF System Validated for Climate TransparencyMiningstockeducation•Feb 06, 2026•Samsung BioLogics
Are you a Founder ?
FAQs about Samsung BioLogics
Explore our recently published companies
- Anurag International - Bulandshahr based, Unfunded company
- Rolexreplica1 - Suriname based, Unfunded company
- Jordan Watches - India based, 2024 founded, Unfunded company
- Bestcoloursolutions - India based, 2008 founded, Unfunded company
- Craftypanther - United Kingdom based, Unfunded company
- Tesbihcibaba - Turkey based, Unfunded company